Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Files An 8-K Submission of Matters to a Vote of Security Holders

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders.

Story continues below

At our Annual Meeting of stockholders held on June12, 2018, our stockholders voted on three matters as follows:

1. The following eight nominees were elected to our Board of Directors to serve for a one-year term expiring at the 2019 annual meeting of stockholders:
Votes For Votes Against Votes Abstaining Broker Non-Votes

David Beier, J.D.

21,793,580 554,589 21,926 24,663,149

Jeffrey Berkowitz, J.D.

21,570,673 777,490 21,932 24,663,149

Anthony B. Evnin, Ph.D.

21,296,364 1,052,348 21,383 24,663,149

Michael G. Kauffman, M.D., Ph.D.

21,352,982 995,180 21,933 24,663,149

Adelene Q. Perkins

21,525,207 790,819 54,069 24,663,149

Norman C. Selby

21,569,799 776,358 23,938 24,663,149

Ian F. Smith

21,737,979 577,977 54,139 24,663,149

Michael C. Venuti, Ph.D.

21,541,511 804,573 24,011 24,663,149
2. A non-binding, advisory proposal on the compensation of the Company’s named executive officers was approved.

Votes For

VotesAgainst VotesAbstaining BrokerNon-Votes


7,831,872 122,558 24,663,149
3. The appointment of Ernst& Young LLP as our independent registered public accounting firm for the current fiscal year was ratified.

Votes For

VotesAgainst VotesAbstaining BrokerNon-Votes


621,460 437,337

About Infinity Pharmaceuticals, Inc. (NASDAQ:INFI)

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.

An ad to help with our costs